Savara Doubles Down on U.S. Launch Prep as Losses Mount
Event summary
- Savara reported a net loss of $40.2M for Q2 2026, up from $30.4M in Q2 2025.
- R&D expenses rose by $1.2M (5.8%) due to higher personnel costs, partially offset by MOLBREEVI program efficiencies.
- General and administrative expenses surged by $8.3M (78.2%) as the company builds its commercial team for a potential U.S. launch.
- Cash reserves stood at $173M as of June 30, 2026, with $30.1M in debt.
The big picture
Savara is prioritizing its U.S. market entry for MOLBREEVI, a recombinant GM-CSF therapy for autoimmune pulmonary alveolar proteinosis (PAP). The company's increased spending on commercial infrastructure reflects its focus on preparing for regulatory approvals and market launch. The biopharmaceutical sector continues to face challenges in balancing aggressive R&D investments with sustainable financial management, particularly for rare disease therapies where patient populations are smaller but unmet needs are critical.
What we're watching
- Regulatory Timing
- The pace at which the FDA, EMA, and MHRA will review MOLBREEVI applications could determine Savara's commercialization timeline.
- Cash Runway
- Whether Savara can maintain its cash reserves while scaling up commercial operations ahead of a potential U.S. launch.
- Market Readiness
- How effectively Savara can establish a commercial infrastructure to support the launch of MOLBREEVI for autoimmune PAP.